Avadel Pharmaceuticals 향후 성장

Future 기준 점검 5/6

Avadel Pharmaceuticals (는) 각각 연간 49.9% 및 15.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 41.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 38.1% 로 예상됩니다.

핵심 정보

49.9%

이익 성장률

41.06%

EPS 성장률

Pharmaceuticals 이익 성장	12.9%
매출 성장률	15.5%
향후 자기자본이익률	38.14%
애널리스트 커버리지	Good
마지막 업데이트	26 Nov 2025

최근 향후 성장 업데이트

Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10

Recent updates

Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes

Oct 23

Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10

A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb

Aug 02

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jun 10

LUMRYZ And REVITALYZ Trials Will Unlock Future Value

May 04 LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.

Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher

May 04

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 11

The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%

Feb 07

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jan 13

The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%

Dec 01

Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky

Nov 22

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07

이익 및 매출 성장 예측

NasdaqGM:AVDL - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	482	171	138	194	5
12/31/2027	453	170	112	147	8
12/31/2026	359	92	80	95	10
12/31/2025	278	19	65	55	5
9/30/2025	249	0	19	35	N/A
6/30/2025	221	-3	5	5	N/A
3/31/2025	194	-26	-25	-25	N/A
12/31/2024	169	-49	-47	-47	N/A
9/30/2024	138	-73	-83	-83	N/A
6/30/2024	95	-106	-114	-114	N/A
3/31/2024	55	-157	-128	-128	N/A
12/31/2023	28	-160	-129	-129	N/A
9/30/2023	9	-159	-116	-116	N/A
6/30/2023	1	-143	-85	-84	N/A
3/31/2023	N/A	-142	-67	-66	N/A
12/31/2022	N/A	-137	-71	-70	N/A
9/30/2022	N/A	-132	-78	-77	N/A
6/30/2022	N/A	-134	-92	-92	N/A
3/31/2022	N/A	-90	-88	-88	N/A
12/31/2021	N/A	-77	-77	-77	N/A
9/30/2021	N/A	-66	-74	-74	N/A
6/30/2021	N/A	-56	-63	-63	N/A
3/31/2021	10	-6	-61	-61	N/A
12/31/2020	22	7	-49	-49	N/A
9/30/2020	33	16	-38	-38	N/A
6/30/2020	48	18	-35	-35	N/A
3/31/2020	55	-21	-29	-29	N/A
12/31/2019	59	-33	-38	-38	N/A
9/30/2019	69	-94	-55	-55	N/A
6/30/2019	75	-101	N/A	-67	N/A
3/31/2019	86	-96	N/A	-86	N/A
12/31/2018	103	-95	N/A	-83	N/A
9/30/2018	117	-40	N/A	-72	N/A
6/30/2018	137	-2	N/A	-55	N/A
3/31/2018	154	30	N/A	-27	N/A
12/31/2017	173	68	N/A	17	N/A
9/30/2017	182	81	N/A	38	N/A
6/30/2017	174	40	N/A	37	N/A
3/31/2017	167	-9	N/A	24	N/A
12/31/2016	150	-41	N/A	19	N/A
9/30/2016	152	28	N/A	38	N/A
6/30/2016	167	19	N/A	61	N/A
3/31/2016	177	23	N/A	79	N/A
12/31/2015	173	42	N/A	84	N/A
9/30/2015	127	-64	N/A	52	N/A
6/30/2015	87	-46	N/A	36	N/A
3/31/2015	43	-49	N/A	17	N/A

애널리스트 향후 성장 전망

수입 대 저축률: AVDL 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.3%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: AVDL (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: AVDL 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: AVDL 의 수익(연간 15.5%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: AVDL 의 수익(연간 15.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: AVDL의 자본 수익률은 3년 후 38.1%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/02 16:09
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Avadel Pharmaceuticals plc는 20명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jason Butler	Citizens JMP Securities, LLC
Chase Knickerbocker	Craig-Hallum Capital Group LLC
Robin Garner Kalley	Craig-Hallum Capital Group LLC

Avadel Pharmaceuticals 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates

Avadel Pharmaceuticals plc Raises Revenue Guidance for the Full Year of 2025

Avadel Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2025

Avadel Pharmaceuticals Reiterates Earnings Guidance for the Year 2025

Price target increased by 8.0% to US$22.90

Consensus revenue estimates increase by 18%, EPS downgraded

Recent updates

Avadel Pharmaceuticals plc Announces Completion of Enrollment in Phase 3 REVITALYZ Trial in Idiopathic Hypersomnia

H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc (NasdaqGM:AVDL) for $ 2.1 billion.

Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes

Alkermes plc (NasdaqGS:ALKS) entered into a definitive agreement to acquire Avadel Pharmaceuticals plc (NasdaqGM:AVDL) for $1.8 billion.

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

Avadel Pharmaceuticals plc to Present New Data on LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension at World Sleep 2025

Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates

Avadel Pharmaceuticals plc Raises Revenue Guidance for the Full Year of 2025

A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb

Avadel Pharmaceuticals plc to Report Q2, 2025 Results on Aug 07, 2025

ASL Strategic Value Fund Files an Exempt Solicitation Statement with Securities and Exchange Commission

ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 29, 2025

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Avadel Pharmaceuticals plc to Present New Data on LUMRYZ™? (sodium Oxybate) for Extended-Release Oral Suspension at Sleep 2025

Avadel Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2025

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

LUMRYZ And REVITALYZ Trials Will Unlock Future Value

Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher

Avadel Pharmaceuticals plc to Report Q1, 2025 Results on May 07, 2025

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

Avadel Pharmaceuticals plc Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

Avadel Pharmaceuticals Reiterates Earnings Guidance for the Year 2025

Avadel Pharmaceuticals plc to Report Q4, 2024 Results on Mar 03, 2025

Avadel Pharmaceuticals: Moving To A Speculative Buy

The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Avadel Pharmaceuticals plc Provides Update on Revitalyz Pivotal Study

Avadel Pharmaceuticals plc Announces Step Down of Richard Kim as Chief Commercial Officer Effective as of December 31, 2024

The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%

Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals plc Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals: Inflection Point Ahead

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension (CIII) Data at Sleep 2024

Avadel Pharmaceuticals plc has completed a Follow-on Equity Offering.

Avadel Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss